Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

Drug discovery has long been criticized for its slow, costly, and failure-prone nature. Traditional approaches, particularly ...

With the rise of advanced simulation and model-informed drug development (MIDD) techniques like digital twins, researchers ...

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...

Learn how AI and machine learning enhance antibody discovery – from structure prediction to binding optimization – with ...

These capabilities illustrate the multifaceted promise of AI: speeding up scientific discovery, improving patient outcomes, ...

The Global Generative Artificial Intelligence (GenAI) in Healthcare Market is expected to witness a growth rate of 36-38% in ...

The FDA has placed the credibility of AI's 'context of use' in pharma development at the heart of its first guidance in this area.

$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx in ...

The way we study new medicines and treatments is changing quickly. One of the biggest reasons for this change is the use of ...

Discover how Agilent's AssayMAP Bravo and RapidFire systems accelerate drug discovery with automation and rapid, reliable ...

The global AI in drug discovery market size was US$ 910.7 million in 2021. The global AI in drug discovery market size is forecast to reach US$ 9,072.2 million by 2030, growing at a compound annual ...